Docetaxel (Taxotere), Vinorelbine, and Bevacizumab, as Adjuvant Chemotherapy for Patients With Resected Stage I-III Non-small Cell Lung Cancer

Inclusion Criteria: * Patients must be at least 2 weeks status post complete (R0) surgical resection of pathologically-proven NSCLC (stage IA-IIIB). Pathology review will be performed independently at MSKCC. * Patients are eligible if they are unfit for cisplatin-based adjuvant chemotherapy based on specified clinical criteria (listed below). * Allergy to cisplatin * Baseline hearing loss (defined as any subjective baseline hearing deficit, even if it does not require a hearing aid or intervention, or interfere with activities of daily life (CTCAE grade \> or equal to 2) * Baseline renal insufficiency (defined as a creatinine clearance of \< than or equal to 60 ml/min as calculated by the equation of Cockcroft and Gault using the patient's age, weight (kg), and serum creatinine (mg/dl). * Performance status 70% on the Karnofsky scale. * Congestive heart failure with New York Heart Association functional classification \> or equal to II, characterized by fatigue, dyspnea or other symptoms which limit activities of daily life. * Patient refuses to take cisplatin. * Age \> than or equal 18 * Performance Status Karnofsky \> than or equal to 70% * Peripheral neuropathy must be \< than grade 1 * Hematologic (minimal values) * Absolute neutrophil count \> than or equal to 1,500/mm3 * Hemoglobin \> than or equal to 8.0 g/dl * Platelet count \> than or equal to 100,000/mm3 Hepatic * Total Bilirubin \< than or equal to 1.5 x ULN AST or ALT and Alkaline Phosphatase must be within the range allowing for eligibility * Women of childbearing potential must have a negative pregnancy test. * Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter. * Patients being considered for treatment with bevacizumab must have a urine protein: creatinine (UPC) ratio \< 1.0 at screening and an MRI of brain or CT brain with IV contrast showing no evidence of brain metastases within 3 months of study entry Exclusion Criteria: * \> 16 weeks post-op * Prior post-operative radiation * \> 1 cycle of prior adjuvant chemotherapy * Patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 80. * Women who are pregnant, or breast-feeding.